Advertisement

Evaluation of the susceptibility of pathogenicCandida species to fluconazole

  • J. Bille
  • M. P. Glauser
  • Fluconazole Global Susceptibility Study Group
Notes

Abstract

A fluconazole 25 ug disk diffusion test was used to test 2230 consecutively isolatedCandida strains from 42 different hospital laboratories in 23 countries. Ninety seven percent of 1634Candida albicans isolates and 83.4% of 596 non-Candida albicans isolates were susceptible to fluconazole, applying the proposed breakpoints (≥26 mm for susceptible strains and 18–25 mm for dosedependent susceptible strains). This is the first hospital laboratory study to evaluate a large number and wide range of sequentialCandida isolates from patients with all types of hospital infections. The fluconazole disk diffusion test appears to be a low-cost, reproducible, and accurate means of assessing the in vitro susceptibility ofCandida isolates.

Keywords

Internal Medicine Laboratory Study Fluconazole Disk Diffusion Susceptible Strain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeast. Tentative standard M27-T. NCCLS, Villanova, PA, 1995.Google Scholar
  2. 2.
    Polanco AM, Rodriguez-Tudela JL, Baquero F, Sanchez-Sousa A, Martinez-Suarez JV: Improved method of determining the susceptibility ofCandida albicans to fluconazole. Journal of Antimicrobial Chemotherapy 1995, 35: 155–159.PubMedGoogle Scholar
  3. 3.
    Fournier C, Gaspar A, Boillot F, Villard J: Evaluation of a broth microdilution antifungal susceptibility test with a pH indicator: comparison with the broth macrodilution procedures. Journal of Antimicrobial Chemotherapy 1995, 35: 373–380.PubMedGoogle Scholar
  4. 4.
    Rodriguez-Tudela JL, Martinez-Suarez JV: Defining conditions for microbroth antifungal susceptibility tests: influence of RPMI-2% glucose on the selection of endpoint criteria. Journal of Antimicrobial Chemotherapy 1995, 35: 739–749.PubMedGoogle Scholar
  5. 5.
    Espinel-Ingroff A, Rodriguez-Tudela JL, Martinez-Suarez JV: Comparison of two microdilution procedures with the proposed NCCLS reference macro-dilution method M27-P for in vitro testing of fluconazole resistant and susceptible isolates ofCandida albicans. Journal of Clinical Microbiology 1995, 33: 3154–3158.PubMedGoogle Scholar
  6. 6.
    Colombo J, Barchiesi F, McGough DA, Fotherfill AW, Rinaldi MG: Evaluation of the E-test system versus a microtitre broth method for antifungal susceptibility testing of yeast against fluconazole and itraconazole. Antimicrobial Agents and Chemotherapy 1995, 36: 93–100.Google Scholar
  7. 7.
    Troillet N, Durussel C, Bille J, Glauser MR Chave JP: Correlation between in vitro susceptibility ofCandida albicans and fluconazole resistant oropharyngeal candidiasis in HIV-infected patients. European Journal of Clinical Microbiology & Infectious Diseases 1993, 12: 911–915.Google Scholar
  8. 8.
    Barry A, Brown S: Fluconazole disk diffusion procedure for determining susceptibility ofCandida species. Journal of Clinical Microbiology 1996, 34: 2154–2157.PubMedGoogle Scholar
  9. 9.
    Rex J, Pfaller MA, Barry AL, Nelson PW, Webb CD: Antifungal susceptibility testing of isolates from a randomized multicenter trial of fluconazole versus amphotericin B as treatment of non-neutropenic patients with candidemia. Antimicrobial Agents and Chemotherapy 1995, 39: 40–44.PubMedGoogle Scholar
  10. 10.
    van't Wout JW: Fluconazole treatment of candidal infections caused by non-albicans Candida species. European Journal of Clinical Microbiology & Infectious Diseases 1996, 15: 238–242.Google Scholar
  11. 11.
    Ghannoum M, Rex JH, Galgiani J: Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. Journal of Clinical Microbiology 1996, 34: 489–495.PubMedGoogle Scholar
  12. 12.
    Rex J, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry A: Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro — in vivo correlation data for fluconazole, itraconazole, andCandida infections. Clinical Infectious Diseases 1997, 24: 235–247.PubMedGoogle Scholar

Copyright information

© MMV Medizin Verlag GmbH 1997

Authors and Affiliations

  • J. Bille
    • 1
  • M. P. Glauser
    • 2
  • Fluconazole Global Susceptibility Study Group
  1. 1.Institute of MicrobiologyCentre Hospitalier Universitaire VaudoisLausanneSwitzerland
  2. 2.Division of Infectious Disease, Department of Internal MedicineCentre Hospitalier Universitaire VaudoisLausanneSwitzerland

Personalised recommendations